LYMPHOBLASTIC LYMPHOMA

This study tests a treatment called WU-CART-007 for people with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that has come back or not responded to other treatments. The therapy uses donor immune cells that are modified to find and attack cancer cells. The main g…

This study tests a new way to prevent chronic graft-versus-host disease (GVHD) in children and young adults with blood cancers who receive a donor stem cell transplant. Researchers remove a specific type of immune cell (naive T cells) from the donor cells before transplant to red…

This study is for children and young adults (ages 1-18) with newly diagnosed B-cell acute lymphoblastic leukemia or lymphoma. It tests a combination of two targeted immunotherapy drugs, inotuzumab and blinatumomab, given early in treatment. The goal is to see if this approach can…

This study tests whether a new version of the drug asparaginase, made from a different bacterium, can be safely combined with standard chemotherapy for high-risk adults (ages 18–54) newly diagnosed with acute lymphoblastic leukemia or lymphoblastic lymphoma. The drug works by bre…

This study tests a new way to prepare stem cells for transplant in children and adults with blood cancers like leukemia. The method removes certain immune cells to lower the risk of graft-versus-host disease, a serious side effect. About 70 participants will receive the treatment…

This study uses a cord blood transplant after strong chemotherapy and radiation to treat various blood cancers like leukemia and lymphoma. About 200 participants will receive the transplant to see if it improves survival one year later. The approach aims to replace diseased bone …

This study tests a mix of chemotherapy drugs (DA-EPOCH) plus the targeted pill ponatinib in adults newly diagnosed with a specific, aggressive leukemia (Ph+ ALL). The goal is to see if this combination can wipe out cancer cells deep in the bone marrow. About 33 people will take p…

This study tests whether adding specially prepared donor immune cells can help children recover from stem cell transplants faster and avoid dangerous infections. Participants are children under 25 with high-risk blood cancers who have already received a transplant. The goal is to…

This study is for people with certain blood cancers, like leukemia or lymphoma. It tests a stem cell transplant from a half-matched donor, using a special drug combo (treosulfan and fludarabine) plus low-dose radiation to prepare the body. The goal is to see if this approach help…

This study tests a new experimental drug, LP-118, combined with three other medicines (ponatinib, vincristine, and dexamethasone) in adults with T-cell acute lymphoblastic leukemia or lymphoma that has come back or not responded to treatment. The main goals are to find a safe dos…

This study tests a treatment called anti-CD19 CAR T-cell therapy for people with advanced B-cell leukemias or lymphomas that haven't responded to standard drugs. Participants' own immune cells are collected, modified to recognize and attack cancer cells, and then returned to the …

This early-stage trial tests a vaccine (CMV-MVA Triplex) given to both stem cell donors and recipients to boost immunity against cytomegalovirus (CMV), a common and dangerous infection after transplant. About 46 people with various blood cancers or disorders will take part. The g…

This study tests a mobile phone program that sends timely reminders and support to help teens and young adults (ages 14-29) with acute lymphoblastic leukemia take their oral chemotherapy as prescribed. The program is designed to adapt to each person's needs in real time. The main…

This study enrolls children and teens (ages 1-18) newly diagnosed with acute lymphoblastic leukemia, lymphoblastic lymphoma, or mixed phenotype acute leukemia. The main goal is to collect enough information about each patient's cancer to determine their risk of the disease return…

This study will look back at the medical records of 18,000 children, adolescents, and young adults with cancer in low- and middle-income countries. The goal is to understand how often treatment fails or causes serious side effects, especially for acute lymphoblastic leukemia and …